Cytosorbents (CTSO) Long-Term Deferred Tax (2018 - 2021)

Cytosorbents (CTSO) has reported Long-Term Deferred Tax for 4 consecutive years, with $35.3 million the latest figure, recorded in Q4 2021.

• For the quarter ending Q4 2021, Long-Term Deferred Tax rose 39.98% year-over-year to $35.3 million; the trailing twelve-month figure through Dec 2021 stood at $35.3 million (up 39.98% YoY), and the FY2021 full-year result was $35.3 million, up 39.98% from the prior year.
• Long-Term Deferred Tax climbed to $35.3 million in Q4 2021 per CTSO's latest filing, from $25.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $35.3 million in Q4 2021 and bottomed at $18.3 million in Q4 2018.
• Historically, Long-Term Deferred Tax has averaged $25.5 million across 4 years, with a median of $24.2 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Long-Term Deferred Tax advanced 8.49% in 2020, then soared 39.98% in 2021.
• Over 4 years, Long-Term Deferred Tax stood at $18.3 million in 2018, then grew by 27.37% to $23.3 million in 2019, then gained by 8.49% to $25.2 million in 2020, then soared by 39.98% to $35.3 million in 2021.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $35.3 million, $25.2 million, and $23.3 million for Q4 2021, Q4 2020, and Q4 2019 respectively.